



Vaccines Addressing COVID-19

Early on during the pandemic, the Food and Drug Administration issued guidance to help expedite the development of COVID-19 vaccines. In the United States, there are three vaccines now authorized or approved for use. These include one of the vaccines that is available for use in individuals at least 5 years of age. Additional primary vaccine doses have also been authorized for certain immunocompromised individuals and boosters have been authorized for all adults. The development of COVID-19 vaccines for the youngest children is currently ongoing, and additional types of COVID-19 vaccines are also under development.

LEARNING OBJECTIVES:

1. Provide an overview of expedited vaccine development
2. Explain the potential importance of vaccine booster doses
3. Discuss the COVID-19 vaccines available for various populations

CONTINUING EDUCATION

CE CREDITS: 1

EDUCATIONAL METHOD: Lecture, Recorded, Self-instructional (self-study)

LOCATION: Online

ORIGINAL RELEASE DATE: June 2022

EXPIRATION DATE: June 30, 2025

RECOGNITION STATEMENT

ADA CER.P® | Continuing Education
Recognition Program

OSAP is an ADA CERP Recognized Provider.

ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry.

Concerns or complaints about a CE provider may be directed to the provider or to the **Commission for Continuing Education Provider Recognition** at ADA.org/CERP.

Please email the OSAP office at office@osap.org or call +1 (410) 571-0003 if you wish to be in contact with the course author/creator(s) with any questions or for clarification of course concepts or for technical assistance in completing the online test.

All participants assume individual responsibility for providing evidence of contact hours of continuing education to the appropriate authorities and for the maintenance of their individual records.

[See more details about OSAP's CE Program & Provider Recognition.](#)

DISCLOSURE:

All participating faculty are expected to disclose to the audience any significant financial interest or other relationship with:

1. the manufacturer of any commercial products and/or provider of commercial services discussed in an educational presentation and
2. any commercial supporters of the activity.

CE DISCLAIMER:

The 2022 OSAP Annual Conference is planned and presented by the 2022 OSAP Annual Conference Planning Committee to provide participants with a relevant and rewarding continuing educational experience. However, neither the content of a course nor the use of specific products in lectures or workshops should be construed as indicating endorsement or approval by OSAP of the views presented or the products used.

Speakers and authors of CE activities are required to present a balanced view of therapeutic options, use generic names of products whenever possible, use images that have not been falsified or misrepresent the outcome of treatment, and refrain from marketing or promoting any products or commercial services. Speakers and authors are required to include peer-reviewed content supported by generally accepted scientific principles or methods that can be substantiated or supported with peer-reviewed scientific literature that is relevant and current. Speakers and authors must support clinical recommendations with references from the scientific literature, with a sound scientific basis, whenever possible. Speakers and authors of CE activities are required to disclose to participants any financial, commercial, or promotional interest in a product or company that may influence their presentations. However, OSAP shall not be liable for a speaker's failure to disclose such interest.

SPEAKERS:

Peter Marks, MD, PhD

DIRECTOR

FDA - Center for Biologics Evaluation and Research (CBER)

Dr. Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women's Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in January 2016.

Disclosures: No relevant financial relationships to disclose